

**TEXAS STATE VITA**

Liqin Du, MD PHD

**I. Academic/Professional Background****A. Educational Background**

PHD, University of Kentucky.

MS, Shanghai Second Medical University (Shanghai Jiao Tong University School of Medicine).

BM (MD equivalent), Shanghai Medical University (Shanghai Medical College of Fudan University, China).

**B. University Experience**

<i>Position</i>	<i>University</i>	<i>Dates</i>
Associate Professor	Texas State University	2021 - Present
Assistant Professor	Texas State University	2015 - 2021
Adjunct Assistant Professor	UT Health Science Center at San Antonio	2015 - Present
Research Assistant Professor	UT Health Science Center at San Antonio	2013 - 2015
Instructor	UT Health Science Center at San Antonio	2012 - 2013
Assistant Instructor	UT Southwestern Medical Center at Dallas	2009 - 2011
Post-doctoral fellow	UT Southwestern Medical Center at Dallas	2005 - 2009
Lecturer	Shanghai Second Medical University, China	1998 - 1999
Research Assistant	Institute of Neurology, Fudan University, China	1992 - 1995

**II. TEACHING****A. Lectures (Texas State University):**

CHEM 4375/5375 - Biochemistry

CHEM 4481 – Advanced Biochemistry Lab I

CHEM 5383 – Molecular Biology and Genetics

CHEM 5387 – Nucleic Acids

**B. Undergraduate/graduate research (Texas State University):**

CHEM 4382 – Advanced Biochemistry Lab II

CHEM 4299 – Undergraduate research

CHEM 4371 – Directed Study

CHEM 5199/5299/5399 – Thesis Research

**C. Directed Student Learning (theses, dissertations, undergraduate research, etc.):****(48, Texas State)**

48) Supervisor / Chair, Applied Research Project, "Characterizing the anti-cancer mechanisms of Rooperol", Status: In Progress. (November 1, 2019 - Present). Biochemistry, Texas State University.

Student(s): Christian Cifuentes, Undergraduate, Bachelor of Science.

47) Supervisor / Chair, Applied Research Project, "Optimization of plasmid transformation protocol in E. coli cells", Status: In Progress. (October 30, 2019 - Present). Biochemistry, Texas State University.

Student(s): Benjamin Collier, Undergraduate, Bachelor of Science.

46) Supervisor / Chair, Applied Research Project, "Correlation of p42.3 gene expression with adult and pediatric cancer patient survival", Status: In Progress. (October 1, 2019 - Present). Biochemistry, Texas State University.

Student(s): Reagan Webber, Undergraduate, Bachelor of Science.

45) Supervisor / Chair, Applied Research Project, "Overexpression of miR-124 and miR-506 in neuroblastoma cells using expression vectors", Status: In Progress. (October 1, 2019 - Present). Biochemistry, Texas State University.

Student(s): Robert Tomestic, Undergraduate, Bachelor of Science.

44) Supervisor / Chair, Applied Research Project, "Identifying miR-506-3p target genes that regulate neuroblastoma cell differentiation", Status: In Progress. (October 1, 2019 - Present). Biochemistry, Texas State University.

Student(s): Tehya McClendon, Undergraduate, Bachelor of Science.

43) Member, Candidacy Exam, "Advances in aptamer discovery and application", Status: Completed. (September 9, 2019 - November 22, 2019). Biochemistry, Texas State University.

Student(s): Rebecca Marks, Graduate, Master of Art.

42) Supervisor / Chair, Master's Thesis, "Cell Cycle Regulator SAPCD2 as a Novel Oncogene in Pediatric Neuroblastoma", Status: In Progress. (August 26, 2019 - Present). Chemistry and Biochemistry, Texas State University.

Student(s): Amy Baker, Graduate, Master of Science.

41) Supervisor / Chair, Applied Research Project, "Novel anti-cancer drugs for neuroblastoma and melanoma", Status: In Progress. (June 2019 - Present). Biochemistry, Texas State University.

Student(s): Liana Tamez, Undergraduate, Bachelor of Science.

40) Supervisor / Chair, Applied Research Project, "miR-506-3p regulate expression of transcription factors PLAGL2 and MYCN in neuroblastoma", Status: Completed. (April 2, 2019 - June 4, 2019). Biochemistry, Texas State University.

Student(s): Collin Bryant, Undergraduate, Bachelor of Science.

- 39) Supervisor / Chair, Applied Research Project, "Discovering target genes of miR-506-3p that mediates its tumor suppressive function", Status: Completed. (January 22, 2019 – May 6, 2019). Biochemistry, Texas State University.  
Student(s): Kaitlin Walla, Undergraduate, Bachelor of Science.
- 38) Member, Master's Thesis, "Novel neuroblastoma differentiation agents", Status: In Progress. (October 2018 - Present). Chemistry and Biochemistry, Texas State University.  
Student(s): Breana Laguera, Graduate, Master of Science.
- 37) Member, Master's Thesis, "Synthesis of Caffeic acid phenethyl amide and analogues for cytotoxicity analysis to improve metabolic stability", Status: In Progress. (October 2018 - Present). Chemistry and Biochemistry, Texas State University.  
Student(s): Mauricio Jemal, Graduate, Master of Science.
- 36) Supervisor / Chair, Applied Research Project, "Improve DNA gel electrophoresis protocol", Status: Completed. (October 2018 - May). Biochemistry, Texas State University.  
Student(s): Seth Paniagua, Undergraduate, Bachelor of Science.
- 35) Supervisor / Chair, Project, "Identification of Anti-cancer drugs for neuroblastoma", Status: In Progress. (October 2018 – August 2019). Biology, Texas State University.  
Student(s): Andrew Gonzales, Undergraduate, Bachelor of Science.
- 34) Supervisor / Chair, Master's Thesis, "Characterizing the anti-cancer activity of three novel differentiation-inducing compounds", Status: *In Progress*. (September 2018 - present). Chemistry and Biochemistry, Texas State University.  
Student(s): Alex Oviedo, Graduate, Master of Science.
- 33) Supervisor / Chair, Master's Thesis, "Determining the cellular response of neuroblastoma cells to miR-506-3p expression", Status: *In Progress*. (September 2018 - present). Chemistry and Biochemistry, Texas State University.  
Student(s): Nathaniel Belnap, Graduate, Master of Science.
- 32) Supervisor / Chair, Applied Research Project, "Identifying synthetic compounds that induce neuroblastoma cell death and differentiation", Status: Completed. (September 2018 – May 2019). Biochemistry, Texas State University.  
Student(s): Courtney Steed, Undergraduate, Bachelor of Science.
- 31) Supervisor / Chair, Applied Research Project, "Identifying natural products that induce neuroblastoma cell death", Status: Completed. (August 2018 – May 2019). Biochemistry, Texas State University.  
Student(s): Carlos Duenas, Undergraduate, Bachelor of Science.
- 30) Supervisor / Chair, Applied Research Project, "Anti-cancer activity of light sensitive compounds", Status: Completed. (July 2018 – May 2019). Biochemistry, Texas State University.  
Student(s): Amy Baker, Undergraduate, Bachelor of Science.
- 29) Supervisor / Chair, Applied Research Project, "correlation of candidate oncogenes and tumor suppressor genes with cancer patient survival", Status: Completed. (July 2018 – May 2019). Biochemistry, Texas State University.  
Student(s): Soroush Omidvarnia, Undergraduate, Bachelor of Science.

- 28) Supervisor / Chair, Project, "Mechanisms by which miR-506-3p regulates MYCN expression in neuroblastoma cells", Status: Completed. (October 2017 – May 2018). Biology, Texas State University.  
Student(s): Ashley Engbrock, Undergraduate, Bachelor of Science.
- 27) Member, Master's Thesis, "Role of spontaneous DNA damage and single-stranded DNA in generation of enlarged G2 phase cells in rad52 mutants of *Saccharomyces cerevisiae*", Status: Completed. (January 2017 - December 2018). Chemistry and Biochemistry, Texas State University.  
Student(s): Corbin England, Graduate, Master of Science.
- 26) Supervisor / Chair, Project, "Novel compounds that induce neuroblastoma cell differentiation and reduce cell survival", Status: Completed. (August 2017 - August 2018). Biology, Texas State University.  
Student(s): Evelyn Shanks, Undergraduate, Bachelor of Science.
- 25) Supervisor / Chair, Applied Research Project, "Making protein ladder used for Western blot analysis", Status: Completed. (October 2017 - May 2018). Biochemistry, Texas State University.  
Student(s): Luke Fuller, Undergraduate, Bachelor of Science.
- 24) Supervisor / Chair, Undergraduate Research, "Culturing neuroblastoma cell lines", Status: In Progress. (October 2017 - May 2018). Biology, Texas State University.  
Student(s): Holase Howard, Undergraduate, Bachelor of Science.
- 23) Supervisor / Chair, Undergraduate Research, "Culturing neuroblastoma cell lines", Status: In Progress. (October 2017 - May 2018). Biology, Texas State University.  
Student(s): Viviana Cavazos, Undergraduate, Bachelor of Science.
- 22) Supervisor / Chair, Applied Research Project, "Identifying cytotoxic rooperol analogs for neuroblastoma cells", Status: In Progress. (September 2017 - May 2018). Biochemistry, Texas State University.  
Student(s): Mary Rodebaugh, Undergraduate, Bachelor of Science.
- 21) Member, Master's Thesis, "Stability studies of rooperol and analogues by in vitro metabolism with HPLC/MS detection", Status: Completed. (September 2017 - May 2019). Chemistry and Biochemistry, Texas State University.  
Student(s): Amanda Bohanon, Graduate, Master of Science.
- 20) Member, Master's Thesis, "Glucuronide prodrug of a naturally derived cytotoxic product", Status: Completed. (September 2017 - May 2019). Chemistry and Biochemistry, Texas State University.  
Student(s): Brandie Tylor, Graduate, Master of Science.
- 19) Supervisor / Chair, Master's Thesis, "Determining the Function of Vacuolar (H<sup>+</sup>)-ATPase in Regulating Neuroblastoma Cell Survival and Differentiation", Status: Completed. (January 23, 2017 - May 2018). Chemistry and Biochemistry, Texas State University.  
Student(s): Geraldo Medrano, Graduate, Master of Science.

- 18) Member, Master's Thesis, "Mechanisms of Cell Death Caused by Photothermal Ablation of Cancer Cells Mediated by Conductive Polymer Nanoparticles.", Status: Completed. (November 1, 2016 - May 2018). Chemistry and Biochemistry, Texas State University. Student(s): Madeline Huff, Graduate, Master of Science.
- 17) Supervisor / Chair, Applied Research Project, "miR-506-3p regulates MYCN expression in neuroblastoma through down regulation of RXR $\alpha$ , specifically truncated RXR $\alpha$ ", Status: Completed. (January 19, 2016 - May 5, 2018). Biology/Biochemistry, Texas State University. Student(s): Spencer Shelton, Undergraduate, Bachelor of Science.
- 16) Supervisor / Chair, Applied Research Project, "Overexpression of VATP06E in neuroblastoma cells", Status: Completed. (October 2017 - March 2018). Biochemistry, Texas State University. Student(s): Raul Nava, Undergraduate, Bachelor of Science.
- 15) Supervisor / Chair, Undergraduate Research, "Novel anti-cancer mechanisms in neuroblastoma", Status: Completed. (January 24, 2017 - December 2017). Biology, Texas State University. Student(s): Cox Grant, Undergraduate, Bachelor of Science.
- 14) Supervisor / Chair, Master's Thesis, "Investigation of the therapeutic potential of miR-506-3p in neuroblastoma", Status: Completed. (October 1, 2015 - August 2017). Chemistry and Biochemistry, Texas State University. Student(s): Michaela Sousares, Graduate, Master of Science.
- 13) Supervisor / Chair, Master's Thesis, "Investigation of the the role of CDKN3 in neuroblastoma cell differentiation", Status: Completed. (October 1, 2015 - August 2017). Chemistry and Biochemistry, Texas State University. Student(s): Veronica Partridge, Graduate, Master of Science.
- 12) Supervisor / Chair, Applied Research Project, "Novel compounds that reduce neuroblastoma survival", Status: Completed. (January 18, 2017 - July 2017). Biology, Texas State University. Student(s): Derek Rodriguez, Undergraduate, Bachelor of Science.
- 11) Member, Master's Thesis, "Aptamer targeted drug delivery and cell-surface biomarker identification for hepatocellular carcinoma", Status: Completed. (July 1, 2016 - July 2017). Chemistry and Biochemistry, Texas State University. Student(s): Elizabeth McIvor, Graduate, Master of Science.
- 10) Supervisor / Chair, Undergraduate Research, "Novel anti-cancer mechanisms in neuroblastoma", Status: Completed. (January 20, 2017 - May 2017). Biology, Texas State University. Student(s): Michael Jones, Undergraduate, Bachelor of Science.
- 9) Supervisor / Chair, Applied Research Project, "Novel compounds that reduce neuroblastoma survival", Status: Completed. (August 29, 2016 - May 2017). Chemistry and Biochemistry, Texas State University. Student(s): Jordan Johnson, Undergraduate, Bachelor of Science.

- 8) Member, Master's Thesis, "Sphaeropsidin A for Cancer Treatment", Status: Completed. (January 1, 2016 - May 2017). Chemistry and Biochemistry, Texas State University. Student(s): Robert Scott, Graduate, Master of Science.
- 7) Supervisor / Chair, Undergraduate research, "Novel anti-cancer mechanisms in neuroblastoma", Status: Completed. (September 8, 2015 - May 2017). Biology, Texas State University. Student(s): Christian Teague, Undergraduate, Bachelor of Science.
- 6) Member, Master's Thesis, "DNA double-strand break repair deficiency is associated with changes in cell cycling and cell morphology in *Saccharomyces cerevisiae*", Status: In Progress. (September 1, 2015 - May 2017). Chemistry and Biochemistry, Texas State University. Student(s): Monica Weis, Graduate, Master of Science.
- 5) Member, Master's Thesis, "Quantitative assessment of changes in cellular morphology and cell division number during telomere-initiated senescence in the yeast *Saccharomyces cerevisiae*", Status: Completed. (January 1, 2016 - December 2016). Chemistry and Biochemistry, Texas State University. Student(s): Shubha Malla, Graduate, Master of Science.
- 4) Supervisor / Chair, Applied Research Project, "Oncogenic role of p42.3 in lung cancer", Status: Completed. (March 6, 2016 - November 1, 2016). Biology, Texas State University. Student(s): Daniel Hernandez, Undergraduate, Bachelor of Science.
- 3) Member, Master's Thesis, "Role of genes affecting telomere lengths, chromatin remodeling, and cell cycle checkpoints in maintenance of chromosome stability in Yeast YKU70 mutant", Status: Completed. (January 1, 2016 - July 2016). Chemistry and Biochemistry, Texas State University. Student(s): Angelica Riojas, Graduate, Master of Science.
- 2) Supervisor / Chair, Undergraduate Research, "Optimizing neuroblastoma cell culturing techniques", Status: Completed. (January 29, 2016 - May 9, 2016). Chemistry and Biochemistry, Texas State University. Student(s): Victoria Sanchez, Undergraduate, Bachelor of Science.
- 1) Supervisor / Chair, Undergraduate Research, "Optimizing neuroblastoma cell culturing techniques", Status: Completed. (January 20, 2016 - May 9, 2016). Chemistry and Biochemistry, Texas State University. Student(s): Cullen Nisson, Undergraduate, Bachelor of Science.

#### **D. Courses Prepared and Curriculum Development: (4, Texas State)**

- 4) CHEM 5387 (Nucleic acids), Revise existing course, Texas State University. Taught: January 2018 - May 2018.
- 3) CHEM 4481 (Advanced Biochem Lab 1), Revise existing course, Texas State University. Taught: August 2017 - December 2017, August 2018 - December 2018, August 2019 - December 2019.

2) CHEM 4375/5375 ( Biochemistry), Revise existing course, Texas State University. Taught: January 2016 - May 2016, January 2017 - May 2017, August 2016 - December 2016.

1) CHEM 5383 (Molecular Biology and Genetics), Revise existing course, Texas State University. Taught: August 2015 - December 2015, August 2016 - December 2016.

## E. Student Accomplishments:

### 1. Award: (3, Texas State)

3) Mentor, Top Master's Poster Award. "Cell Cycle Regulator SAPCD2 Contributes to Poor Prognosis in Pediatric Neuroblastoma," 11th Annual International Research Conference for Graduate Students, Texas State University. Status: Completed. (November 5, 2019). Chemistry and Biochemistry, Texas State University.

Student(s): Amy Baker, Graduate, Master of Science.

2) Mentor, Outstanding undergraduate research award. "RXRA is a direct target gene of miR-506-3p that regulates MYCN expression and cell differentiation in neuroblastoma," Texas State University. Status: Completed. (March 2018). Chemistry and Biochemistry, Texas State University.

Student(s): Spencer Shelton, Undergraduate, BS.

1) Mentor, First Place Undergraduate Poster Presentation Award. "RXRA is a direct target gene of miR-506-3p that regulates MYCN expression and cell differentiation in neuroblastoma," 2017 Department of Biochemistry and Structural Biology Annual Retreat in UT Health Science Center at San Antonio (UTHSCSA), UT Health Science Center at San Antonio (UTHSCSA). Status: Completed. (November 3, 2017). Chemistry and Biochemistry, Texas State University.

Student(s): Spencer Shelton, Undergraduate.

### 2. Peer-reviewed journal articles: (7, Texas State) (see page 7, III. Publications A.)

### 3. Published abstracts: (5, Texas State) (see page 11, III. Publications C.)

### 4. Poster and oral presentations: (16, Texas State) (see page 13, IV. Poster presentations)

## III. Publications

### A. Refereed Journal Articles: (Total, 34; corresponding author, 12; Texas State, 11)

(\*, corresponding author; #, Texas State undergraduate; \$, Texas State graduate)

34) Zhao, Z., #Shelton, S. D., \$Oviedo, A., \$Baker, A. L., #Bryant, C. P., #Omidvarnia, O., \*Du, L., (2020). The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression. *J Exp and Clin Cancer Res*. In press.  
Impact factor: 5.646

- 33) Kosti, A., **Du, L.**, Shivram, H., Qiao, M., Burns, S., Garcia, J. G., Pertsemlidis, A., Iyer, V. R., Kokovay, E., Penalva, L. O. F., (2019). *ELF4* Is a Target of miR-124 and Promotes Neuroblastoma Proliferation and Undifferentiated State. *Mole Cancer Res*, 18(1), 68–78. <https://doi.org/10.1158/1541-7786.MCR-19-0187>  
*Impact factor: 4.484*
- 32) Aksenov, A. V., Aksenov, D. A., Arutiunov, N. A., Aksenov, N. A., Aleksandrova, E. V., Zhao, Z., **Du, L.**, Kornienko, A., Rubin, M. (2019). Synthesis of Spiro[indole-3,5'-isoxazoles] with Anticancer Activity via a Formal [4 + 1]-Spirocyclization of Nitroalkenes to Indoles. *The J Org Chem*, 84(11), 7123–7137. <https://doi.org/10.1021/acs.joc.9b00808>.  
*Impact factor: 4.805*
- 31) Zhao, Z., <sup>§</sup>Partridge, V., <sup>§</sup>Sousares, M., <sup>#</sup>Shelton, S. D., Holland, C., Pertsemlidis, A., & **\*Du, L.** (2018). microRNA-2110 functions as a tumor suppressor in neuroblastoma by directly targeting *Tsukushi*. *PLOS One*, 13(12), e0208777.  
*Impact factor: 2.776*
- 30) **\*Du, L.**, Zhao, Z., Suraokar, M., <sup>#</sup>Shelton, S. D., Ma, X., Hsiao, T. H., Minna, J. D., Wistuba, I., Pertsemlidis, A., LMO1 functions an oncogene through regulating TTK expression and correlates with neuroendocrine differentiation of lung caner. *Oncotarget*. 2018; 9, 29601–29618.  
*Impact factor: 5.008* (2016)
- 29) Yu, X., Zhang, Y., Cavazos, D., Ma, X., Zhao, Z., **Du, L.**, & Pertsemlidis, A. (2018). miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. *Cell Death Dis*, 9(2), 193.  
*Impact factor: 5.959*
- 28) Rastogi, S. K., Zhao, Z., Barrett, S. L., <sup>#</sup>Shelton, S. D., Zafferani, M., Anderson, H. E., Blumenthal, M. O., Jones, L.R., Wang, L., Li, X., Streu, C.N., **Du, L.**, Brittain, W. J. (2018). Photoresponsive azo-combretastatin A-4 analogues. *Eur J Med Chem*, 143, 1–7. <https://doi.org/10.1016/j.ejmech.2017.11.012>  
*Impact factor: 4.816*
- 27) <sup>§</sup>Sousares, M., <sup>§</sup>Partridge, V., Weigum, S., & **\*Du, L.** (2017). MicroRNAs in neuroblastoma differentiation and differentiation therapy. *Adv Mod Oncol Res*, 3(5), 213. <https://doi.org/10.18282/amor.v3.i5.233>
- 26) Li, L.-Y., Ma, R.-L., **\*Du, L.**, & Wu, A.-S. (Published). Ozonated autohemotherapy modulates the serum levels of inflammatory cytokines in gouty Patients. *J Open Acc Rheu: Res Rev*.  
*Impact factor: 0.85*
- 25) <sup>§</sup>Partridge, V., <sup>§</sup>Sousares, M., Zhao, Z., & **\*Du, L.** (2017). Current understanding on the role of cell cycle regulators in neuroblastoma. *Med One*, 2, e170010. <https://doi.org/10.20900/mo.20170010>
- 24) Zhao, Z., Ma, X., <sup>#</sup>Shelton, S. D., Sung, D. C., Li, M., <sup>#</sup>Hernandez, D., ... **\*Du, L.** (2016). A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells. *Oncotarget*, 7(48), 79372–79387. <https://doi.org/10.18632/oncotarget.12676>  
*Impact factor: 5.008* (2016)



23) Zhao, Z., Ma, X., Sung, D., Li, M., Kosti, A., Lin, G., ... **\*Du, L.** (2015). microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest. *RNA Biol*, 12(5), 538–554.

*Impact factor: 5.216*

22) Borkowski, R., **Du, L.**, Zhao, Z., McMillan, E., Kosti, A., Yang, C., ... Pertsemlidis, A. (2015). Genetic Mutation of p53 and Suppression of the 3 miR-17-92 Cluster Are Synthetic Lethal in Non-Small Cell Lung Cancer due to Upregulation of Vitamin D Signaling. *Cancer Res*, 75(4), 666–75. <https://doi.org/10.1158/0008-5472>

*Impact factor: 9.130*

21) Zhao, Z., Ma, X., Hsiao, T., Lin, G., Kosti, A., Yu, X., ... **\*Du, L.** (2014). A high-content morphological screen identifies novel microRNAs that regulate neuroblastoma cell differentiation. *Oncotarget*, 5(9), 2499–512.

*Impact factor: 5.008* (2016)

20) **\*Du, L.**, Zhao, Z., Ma, X., Hsiao, T., Chen, Y., Young, E., ... Pertsemlidis, A. (2014). miR-93-directed down-regulation of DAB2 defines a novel oncogenic pathway in lung cancer. *Oncogene*, 33, 4307–4315.

*Impact factor: 6.854*

19) **Du, L.**, Borkowski, R., Zhao, Z., Yu, X., Ma, X., & Pertsemlidis, A. (2013). A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel. *RNA Biol*, 10(11), 1700–1713.

*Impact factor: 5.216*

18) **Du, L.**, & Pertsemlidis, A. (2012). microRNA regulation of cell viability and drug sensitivity in lung cancer. *Exp Opin Biol Ther*, 12(9), 1221–1239.

*Impact factor: 3.974*

17) **Du, L.**, Subauste, M., DeSevo, C., Zhao, Z., Baker, M., Borkowski, R., ... Pertsemlidis, A. (2012). miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. *PLOS One*, 7(6), e39167.

*Impact factor: 2.776*

16) **Du, L.**, & Pertsemlidis, A. (2011). Cancer and neurodegenerative disorders: pathogenic convergence through microRNA regulation. *J Mol Cell Biol*, 3(3), 176–80.

*Impact factor: 4.671*

15) Subauste, M., Ventura-Holman, Lu, D., **Du, L.**, Sansoma, O., & Maher, J. (2011). Fem1b antigen in the stool of Apc (Min) mice as a biomarker of early Wnt signaling activation in intestinal neoplasia. *Cancer Epidemiol*, 35(1), 97–100.

*Impact factor: 2.619*

14) Nikolic, D., Calderon, L., **Du, L.**, & Post, S. (2011). SR-A ligand and M-CSF dynamically regulate SR-A expression and function in primary macrophages via p38 MAPK activation. *BMC Immunol*, 12, 37–46.

*Impact factor: 2.615*

13) Subauste, M., Sansom, O., Porecha, N., Raich, N., **Du, L.**, & Maher, J. (2010). Fem1b, a proapoptotic protein, mediates proteasome inhibitor-induced apoptosis of human colon cancer cells. *Mol Carcinog*, 49(2), 105–13.

*Impact factor: 3.411*

- 12) \***Du, L.**, Schageman, J., Irnov, Girard, L., Hammond, S., Minna, J., ... Pertsemlidis, A. (2010). microRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. *J Exp Clin Cancer Res*, 29, 75.  
*Impact factor: 5.646*
- 11) **Du, L.**, & Pertsemlidis, A. (2010). microRNAs and lung cancer: tumors and 22-mers. *Cancer Metast Rev*, 29(1), 109–22.  
*Impact factor: 6.667*
- 10) Gibbons, D., Lin, W., Creighton, C., Rizvi, Z., Gregory, P., Goodall, G., Thilaganathan, N., **Du, L.**, Zhang, Y., Pertsemlidis, A., Kurie, J. (2009). Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. *Genes Dev*, 23(18), 2140–2151.  
*Impact factor: 8.990*
- 9) \***Du, L.**, Schageman, J., Subauste, M., Saber, B., Hammond, S., Prudkin, L., ... Pertsemlidis, A. (2009). miR-93, miR-98 and miR-197 regulate expression of tumor suppressor gene. *FUS1. Mol Cancer Res*, 7(8), 1234–1243.  
*Impact factor: 4.484*
- 8) Subauste, M., Ventura-Holman, T., **Du, L.**, Subauste, J., Chan, S., Yu, V., & Maher, J. (2009). RACK1 downregulates levels of the pro-apoptotic protein Fem1b in apoptosis-resistant colon cancer cells. *Cancer Biol Ther*, 8(23), 2297–2305.  
*Impact factor: 2.879*
- 7) **Du, L.**, & Post, S. (2004). Macrophage-colony stimulating factor differentially regulates low-density lipoprotein and transferrin receptor. *J Lipid Res*, 45(9), 1733–1740.  
*Impact factor: 4.743*
- 6) **Du, L.**, Cheng, W., Shi, Q., & Jin, H. (2000). Effect of selenium on the immune responses in normal-immune and immune suppressed mice. *J Shanghai 2nd Med Univ*, 20(1), 29–31.
- 5) **Du, L.**, Cheng, W., Shi, Q., & Gao, M. (2000). Toxic effects of selenium on normal-immune and immune-suppressed mice. *Shanghai Trace Elements. Shanghai Trace Elements*, 1(3), 18–21.
- 4) **Du, L.**, & Cheng, W. (1999). Selenium and Immune Responses. *Foreign Med Sci (Pub Health)*, 26(2), 91–94.
- 3) **Du, L.**, & Cheng, W. (1998). Clinical use of selenium in parenteral nutrition. *Foreign Med Sci (Medical Geology)*, 19(1), 4–8.
- 2) Tian, M., Ye, K., **Du, L.**, & Li, Y. (1994). Assay of hemoagglutinin inhibition antibody to hemorrhagic fever virus. *Shanghai J Med Lab Sci*, 9(1), 40–41.
- 1) Ye, K., **Du, L.**, Tian, M., Zhou, L., Li, Y., & Yu, Z. (1993). An investigation on wild animal reservoir infected with epidemic hemorrhagic fever. *Chinese J Pub Health*, 12(6), 352–354.

**B. Patents: (1)**

**Du, L.** "microRNA composition in the treatment of neuroblastoma". International. Number / ID: US10087444 B2. (Date Awarded: 2018).

**C. Published abstracts: (total, 19; Texas State, 10)**

**(#, Texas State Undergraduate; \$, Texas State graduate)**

19) <sup>\$</sup>Baker, L. A., Zhao, Z., Du, L. (2021). SAPCD2 is potential oncogene that contributes to the poor survival of neuroblastoma patients. *AACR*

19) <sup>\$</sup>Baker, L. A., Zhao, Z., Du, L. (April 19, 2020). Investigation of the Oncogenic Role of the Cell Cycle Regulator SAPCD2 in Pediatric Neuroblastoma. *FASEB Journal*, 34 (No.1 Suppl). <https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.2020.34.s1.09263>

18) <sup>\$</sup>Jemal, M. A., Schwartz, Z. T., Zhao, Z., **Du, L.**, Kerwin K. M. (April 2019). Overcoming the Rapid Metabolism of the Promising Anticancer Natural Product Rooperol. *FASEB Journal*, 33(No.1 Suppl). [https://www.fasebj.org/doi/abs/10.1096/fasebj.2019.33.1\\_supplement.634.5](https://www.fasebj.org/doi/abs/10.1096/fasebj.2019.33.1_supplement.634.5)

17) <sup>#</sup>Shelton, S. D., Zhao, Z., **Du, L.** RXRA is a direct target gene of miR-506-3p that regulates oncogene MYCN expression and cell differentiation in neuroblastoma. *FASEB Journal*, 32(No.1 Suppl). (April, 2018). [https://www.fasebj.org/content/32/1\\_Supplement/804.16](https://www.fasebj.org/content/32/1_Supplement/804.16)

16) <sup>\$</sup>Medrano, G., Zhao, Z., **Du, L.** The Role of the Vacuolar (H<sup>+</sup>)-ATPase in Neuroblastoma Cell Differentiation induced by microRNA 506-3p. *FASEB Journal*, 32(No.1 Suppl). (April, 2018). [www.fasebj.org/content/32/1\\_Supplement/804.3](http://www.fasebj.org/content/32/1_Supplement/804.3)

15) <sup>\$</sup>Sousares, M., **Du, L.**, MicroRNA-506-3p as a Differentiation Agent for Neuroblastoma. (April, 2017). *FASEB Journal*, 31(No.1 Suppl). [www.fasebj.org/content/31/1\\_Supplement/757.18](http://www.fasebj.org/content/31/1_Supplement/757.18)

14) <sup>\$</sup>Partridge, V., **Du, L.**, The Role of CDKN3 in Neuroblastoma Differentiation. *FASEB Journal*, 31(No.1 Suppl). (April, 2017). <http://www.fasebj.org/action/doSearch?AllField=The+Role+of+CDKN3+in+Neuroblastoma+Differentiation>

13) Zhang, Y., Ma, X., Yu, X., Patolia, H., Zhao, Z., **Du, L.**, & Pertsemilidis, A. (2017). ncRNA regulation of eribulin response in neuroblastoma. *Cancer Research*, 77(13 Supplement). [https://cancerres.aacrjournals.org/content/77/13\\_Supplement/3506](https://cancerres.aacrjournals.org/content/77/13_Supplement/3506)

12) Yu, X., Ma, X., Zhang, Y., Zhao, Z., **Du, L.**, & Pertsemilidis, A. (2017). Therapeutic potential of miR-195 in nonsmall cell lung cancer. *Cancer Research*, 77(13 Supplement). [https://cancerres.aacrjournals.org/content/77/13\\_Supplement/5444](https://cancerres.aacrjournals.org/content/77/13_Supplement/5444)

11) Yu, X., Zhao, Z., Ma, X., **Du, L.**, & Pertsemilidis, A. (2016). miR-195 represses the tumorigenesis of non-small cell lung cancer and synergizes with microtubule targeting agents. *Cancer Research*, 76(14 Supplement). [https://cancerres.aacrjournals.org/content/76/14\\_Supplement/1063](https://cancerres.aacrjournals.org/content/76/14_Supplement/1063)

- 10) Ma, X., Yu, X., Zhao, Z., Patolia, H., **Du, L.**, & Pertsemilidis, A. (2016). Non-coding RNA regulation of eribulin response in neuroblastoma. *Cancer Research*, 76(14 Supplement). [https://cancerres.aacrjournals.org/content/76/14\\_Supplement/1940](https://cancerres.aacrjournals.org/content/76/14_Supplement/1940)
- 9) Yu, X., Zhao, Z., Ma, X., **Du, L.**, Pertsemilidis, A., Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, "A high-throughput screen identifies microRNAs regulating lung cancer cell survival and response to paclitaxel," San Diego, CA, United States. (April 5, 2014). *Cancer Research*, 74(19 Supplement). [https://cancerres.aacrjournals.org/content/74/19\\_Supplement/3545](https://cancerres.aacrjournals.org/content/74/19_Supplement/3545)
- 8) Zhao, Z., Ma, X., Hsiao, T.-H., Chen, Y., Suraokar, M., Wistuba, I., Minna, J. D., Pertsemilidis, A., **Du, L.**, Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, "LMO1 is a novel oncogene in neuroendocrine lung cancer," San Diego, CA, United States. (April 5, 2014). *Cancer Research*, 74(19 Supplement). [https://cancerres.aacrjournals.org/content/74/19\\_Supplement/466](https://cancerres.aacrjournals.org/content/74/19_Supplement/466)
- 7) DeSevo, C., **Du, L.**, Behrens, C., Wistuba, I., Minna, J. D., & Pertsemilidis, A. (2013). miR-10a regulates PI3K signaling and paclitaxel response in NSCLC. *Cancer Research*, 73(8 Supplement). [https://cancerres.aacrjournals.org/content/73/8\\_Supplement/3049](https://cancerres.aacrjournals.org/content/73/8_Supplement/3049)
- 6) **Du, L.**, Zhao, Z., Hsiao, T.-H., Chen, Y. F., Young, E., Suraokar, M., Wistuba, I., Minna, J. D., Pertsemilidis, A., Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, "miR-93-directed down-regulation of DAB2 defines a novel oncogenic pathway in lung cancer," Washington DC, United States. (April 6, 2013). *Cancer Research*, 73(8 Supplement). [https://cancerres.aacrjournals.org/content/73/8\\_Supplement/3096](https://cancerres.aacrjournals.org/content/73/8_Supplement/3096)
- 5) **Du, L.**, DeSevo, C., Borkowski, R., Baker, M., Minna, J. D., & Pertsemilidis, A. (2012). microRNA regulation of cell viability and drug response in cancer. *Cancer Res*, 72(8 Supplement). [https://cancerres.aacrjournals.org/content/72/8\\_Supplement/140](https://cancerres.aacrjournals.org/content/72/8_Supplement/140)
- 4) DeSevo, C., **Du, L.**, Behrens, C., Minna, J. D., & Pertsemilidis, A. (2012). miR-10a regulation of PIK3CA and response to taxol in non small cell lung cancer. *Cancer Res*, 72(2 Supplement). [https://cancerres.aacrjournals.org/content/72/2\\_Supplement/A2](https://cancerres.aacrjournals.org/content/72/2_Supplement/A2)
- 3) **Du, L.**, DeSevo, C., Borkowski, R. F., Baker, M., Gazdar, A. F., Minna, J. D., Pertsemilidis, A., Noncoding RNAs and Cancer, American Association for Cancer Research, "microRNA regulation of cell viability and drug sensitivity in lung cancer," Miami Beach, FL, United States. (January 8, 2012). *Cancer Res*, 72(2 Supplement). [https://cancerres.aacrjournals.org/content/72/2\\_Supplement/B7](https://cancerres.aacrjournals.org/content/72/2_Supplement/B7)
- 2) Borkowski, R., **Du, L.**, Minna, J. D., Gazdar, A., Pertsemilidis, A., Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research, "A miRNA inhibitor screen for synthetic lethal interactions in KRAS-driven NSCLC," Orlando, FL, United States. (April 2, 2011). *Cancer Res*, 71(8 Supplement). [https://cancerres.aacrjournals.org/content/71/8\\_Supplement/3958](https://cancerres.aacrjournals.org/content/71/8_Supplement/3958)
- 1) **Du, L.**, Subauste, M. C., Baker, M. D., DeSevo, C., Borkowski, R., Zhong, S., Schageman, J. J., Greer, R. M., Yang, C. R., Girard, L., Gazdar, A. F., Wistuba, I. I., Minna, J. D., Pertsemilidis, A., Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research, "miR-337-3p and its targets STAT3 and RAP1A modulate paclitaxel sensitivity in non-small cell lung cancers (NSCLCs)," Orlando, FL, United States. (April 2,

2011). *Cancer Res*, 71(8 Supplement).

[https://cancerres.aacrjournals.org/content/71/8\\_Supplement/4709](https://cancerres.aacrjournals.org/content/71/8_Supplement/4709)

#### **IV. Poster presentations: (total, 39; Texas State, 18)**

##### **(#, Texas State Undergraduate; \$, Texas State graduate)**

40) <sup>\$</sup>Baker, L. A., Zhao, Z., Du, L. (2021). Investigating the role of SAPCD2 in modulating neuroblastoma cell survival and differentiation

39) <sup>\$</sup>Oviedo, A., Zhao, Z., Du, L. The Annual Biomedical Research Conference for Minority Students (ABRCMS) 2019, "Characterizing the Activity of Three Novel Differentiation-inducing Small Compounds in Neuroblastoma Cell Lines," ABRCMS, Anaheim, CA, United States. (November 13, 2019).

38) <sup>\$</sup>Baker, A. L., Zhao, Z., **Du, L.** The 11th Annual International Research Conference (IRC) 2019, "Cell Cycle Regulator SAPCD2 Contributes to Poor Prognosis in Pediatric Neuroblastoma," Texas State University, San Marcos, TX, United States. (November 5, 2019).

37) <sup>\$</sup>Oviedo, A., Zhao, Z., **Du, L.** The 11th Annual International Research Conference (IRC) 2019, "Discovery of novel differentiation-inducing compounds for treating neuroblastoma cell lines," Texas State University, San Marcos, TX, United States. (November 5, 2019).

36) <sup>#</sup>Gonzales, A., Zhao, Z., **Du, L.**, The 2nd Annual Undergraduate Research Symposium 2019, "Characterizing The Activity of a Novel Differentiation-Inducing Compound in Neuroblastoma Cells," Texas State University, San Marcos, CA, United States. (August 2, 2019).

35) <sup>\$</sup>Laguera, B., Zhao, Z., **Du, L.**, Kornienko, A. 2019 Center of Innovative Drug Design (CIDD) Drug Discovery Symposium, "Novel Neuroblastoma Differentiating Agents," University of Texas at San Antonio, San Antonio, TX, United States. (April 29, 2019).

34) <sup>#</sup>Johns, A., Zhao, Z., **Du, L.**, Kornienko, A. 2019 Center of Innovative Drug Design (CIDD) Drug Discovery Symposium, "Structure Activity Relationship Study of a Novel Neuroblastoma Differentiation Agent," University of Texas at San Antonio, San Antonio, TX, United States. (April 29, 2019).

33) <sup>\$</sup>Oviedo, A., Zhao, Z., Kornienko, A. V., **Du, L.** 2019 Women in Science and Engineering Conference (WISE), "Characterizing activity of three novel differentiation-inducing small synthetic compounds in neuroblastoma cell line BE(2)-C," Texas State University, San Marcos, TX, United States. (March 8, 2019).

32) <sup>#</sup>Johns, A., Zhao, Z., **Du, L.**, Kornienko, A. 2018 UTSA College of Sciences Research in Service for a Better Tomorrow conference, "Preparation of a Mechanistic Probe for a Neuroblastoma Differentiation Agent," University of Texas at San Antonio, San Antonio, TX, United States. (October 5, 2018).

31) <sup>#</sup>Johns, A., Zhao, Z., **Du, L.**, Kornienko, A. 2018 The 12th Annual Undergraduate Research Conference of Texas State, "Preparation of a Mechanistic Probe for a Neuroblastoma Differentiation Agent," Texas State University, San Marcos, TX, United States. (April 20, 2018).

- 30) <sup>#</sup>Johns, A., Hooper, A., Zhao, Z., **Du, L.**, Kornienko, A. Texas State Chemistry & Biochemistry Colloquium, "Preparation of a Mechanistic Probe for a Neuroblastoma Differentiation Agent," Texas State University, Dept of Chemistry and Biochemistry, San Marcos, TX, United States. (April 6, 2018).
- 29) <sup>#</sup>Shelton, S. D., Zhao, Z., **Du, L.**, Texas State Chemistry & Biochemistry Colloquium, "RXRA is a direct target gene of miR-506-3p that regulates MYCN expression and cell differentiation in neuroblastoma," Texas State University, Dept of Chemistry and Biochemistry, San Marcos, TX, United States. (April 6, 2018). Oral presentation.
- 28) <sup>#</sup>Shelton, S. D., Zhao, Z., **Du, L.**, Central Texas Region American Chemical Society Centennial Celebration, "RXRA is a direct target gene of miR-506-3p that regulates MYCN expression and cell differentiation in neuroblastoma," Central Texas American Chemistry Society, Oasis Restaurant on Lake Travis, Austin, TX, United States. (November 10, 2017).
- 27) <sup>§</sup>Medrano, G., Zhao, Z., **Du, L.**, Ninth Annual International Research Conference for Graduate Students, "The Role of the Vacuolar (H<sup>+</sup>)-ATPase in Neuroblastoma Cell Differentiation induced by microRNA-506-3p," Texas State University, San Marcos, TX, United States. (November 7, 2017).
- 26) <sup>#</sup>Shelton, S. D., Zhao, Z., **Du, L.**, UT Health San Antonio, Department of Biochemistry and Structural Biology Annual Retreat, "RXRA is a direct target gene of miR-506-3p that regulates MYCN expression and cell differentiation in neuroblastoma," UT Health Science Center at San Antonio, GCCRI building, San Antonio, TX, United States. (November 3, 2017).
- 25) <sup>§</sup>Medrano, G., Zhao, Z., **Du, L.**, Summer Capstone Symposium, "Determining the Function of Vacuolar (H<sup>+</sup>)-ATPase in Regulating Neuroblastoma Cell Survival and Differentiation," UT Health Science Center at San Antonio, San Antonio, TX, United States. (August 11, 2017).
- 24) <sup>#</sup>Shelton, S. D., Zhao, Z., **Du, L.**, SMBE 2017: Annual Meeting of the Society of Molecular Biology and Evolution, "Defining the mechanisms by which miR-506-3p regulates MYCN expression," SMBE, JW Marriott Austin Hotel, Austin, TX, United States. (July 1, 2017).
- 23) Betancourt, T., **Du, L.**, Kornienko, A. V., Kerwin, S. M., Irvin, J. A., Lewis, L., Beall, G. W., Texas State University Health Scholar Showcase, "Drug Delivery and Therapeutics Research," Texas State University, San Marcos, TX. (February 2017).
- 22) Betancourt, T., David, W., **Du, L.**, Kang, H.-G., Kerwin, S., Lewis, K., Sun, S., Zhao, Q., 2017 Health Scholar Showcase, "Cancer, Genetics, and Bioinformatics," Texas State University, San Marcos, TX, United States. (February 10, 2017).
- 21) Ma, X., Li, M., Zhao, Z., Pertsemliadis, A., Sung, D., **Du, L.**, Greehey Children's Cancer Research Institute 2014 Symposium, "Crosstalk between MYCN and differentiation-inducing microRNAs in neuroblastoma," The University of Texas Health Science Center, Greehey Children's Cancer Research Institute, San Antonio, TX, United States. (November 21, 2014).
- 20) Zhao, Z., Ma, X., Li, M., Kostis, A., Lin, G., Chen, Y., Pertsemliadis, A., Hisao, T. H., **Du, L.**, Greehey Children's Cancer Research Institute 2014 Symposium, "microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell

cycle arrest," The University of Texas Health Science Center, Greehey Children's Cancer Research Institute, San Antonio, TX, United States. (November 21, 2014).

19) Li, M., Ma, X. (co-author), Pertsemlidis, A., **Du, L.**, The University of Texas Health Science Center 2014 Summer research Program, "MYCN regulates the response of neuroblastoma cells to differentiation-inducing microRNAs," The University of Texas Health Science Center, Greehey Children's Cancer Research Institute, San Antonio, TX, United States. (August 5, 2014).

18) DeSevo, C., **Du, L.**, Behrens, C. F., Wistuba, I. I., Minna, J. D., Pertsemlidis, A., Cancer Prevention and Research Institute of Texas, "miR-10a regulation of PIK3CA, Innovations in Cancer Prevention and Research Conference," Austin, TX, United States. (November 15, 2011).

17) **Du, L.**, Subauste, M. C., Baker, M. F., DeSevo, C., Borkowski, R., Zhong, S., Schageman, J. J., Greer, R. M., Yang, C., Gazdar, A. F., Wistuba, I., Minna, J. D., Pertsemlidis, A., Cancer Prevention and Research Institute of Texas, "miR-337-3p modulates sensitivity to paclitaxel in non-small cell lung cancer by down-regulating STAT3 and RAP1A," Austin, TX, United States. (November 17, 2010).

16) Borkowski, R., **Du, L.**, Gazdar, A. F., Minna, J. D., Pertsemlidis, A., 60th Annual Meeting of the American Society of Human Genetics, "An miRNA inhibitor screen for KRAS-selectively lethal miRNAs," Washington, DC, United States. (November 2, 2010).

15) Gibbons, D. L., Gregory, P. A., Lin, W., **Du, L.**, Creighton, C., Pertsemlidis, A., Kurie, J., Keystone Symposium on miRNA and Cancer, "A murine model of NSCLC demonstrates a role for the miR-200 family in regulating EMT and metastasis," Denver, CO, United States. (June 10, 2009).

14) **Du, L.**, Greer, R. M., Saber, B., Gazdar, A., White, M. A., Minna, J. D., Pertsemlidis, A., Keystone Symposium on miRNA and Cancer, "miR-337 modulates sensitivity to paclitaxel in non-small cell lung cancer," Denver, CO, United States. (June 10, 2009).

13) **Du, L.**, Greer, R., Saber, B., Gazdar, A. F., White, M. I., Minna, J. D., Pertsemlidis, A., 100th Annual Meeting of the American Association of Cancer Research, "miR-337-3p modulates sensitivity to paclitaxel in non-small cell lung cancer," Denver, CO, United States. (April 2009).

12) Pertsemlidis, A., **Du, L.**, Greer, R., Gazdar, A. F., Hammond, S., White, M., Minna, J. D., 58th Annual Meeting of the American Society of Human Genetics, "microRNA regulation of chemoresistance in NSCLC," Philadelphia, PA, United States. (November 11, 2008).

11) **Du, L.**, Schageman, J., Hammond, S., Prudkin, L., Wistuba, I. I., Ji, L., Roth, J. A., Minna, J., pertsemlidis, A., 58th Annual Meeting of the American Society of Human Genetics, "miR-93, miR-98 and miR-197 regulate expression of tumor suppressor gene FUS1," Philadelphia, PA, United States. (November 11, 2008).

10) **Du, L.**, Greer, R. M., Schageman, J., Gazdar, A. F., Hammond, S., White, M., Minna, J., pertsemlidis, A., Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, "microRNA regulation of chemoresistance in non-small cell lung cancer (NSCLC)," San Diego, CA, United States. (April 12, 2008).

- 9) Pertsemlidis, A., **Du, L.**, Greer, R. M., Schageman, J., Girard, L., Peyton, M., Gazdar, A. F., Hammond, S., Minna, J., Keystone Symposium on MicroRNA and Cancer, "microRNAs modulate chemotherapy sensitivity of non-small cell lung cancer (NSCLC)," Keystone, CO, United States. (June 18, 2007).
- 8) **Du, L.**, Schageman, J., Goodson, S., Thompson, J. M., Greer, R., Hammond, S., Girard, L., Sato, M., Peyton, M., Gazdar, A. F., Minna, J., Pertsemlidis, A., Fourth Annual Postdoctoral Symposium & Poster Session, "Elucidating the role of microRNAs in lung cancer," The University of Texas Southwestern Medical Center at Dallas, New Orleans, LA, United States. (2006).
- 7) Pertsemlidis, A., Inorv., **Du, L.**, Schageman, J., Goodson, S., Thompson, J. M., Hammond, S., Girard, L., Sato, M., Shay, J., Gazdar, A. F., Minna, J., 56th Annual Meeting of the American Society of Human Genetics, "MicroRNA expression profiling of lung cancer cell lines," American Society of Human Genetics, New Orleans, LA, United States. (October 9, 2006).
- 6) **Du, L.**, Schageman, J., Minna, J., pertsemlidis, A., Third Annual Postdoctoral Symposium & Poster Session, "miR-98 as a Potential Diagnostic Marker and Therapeutic Target in Lung Cancer," The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, United States. (2005).
- 5) **Du, L.**, Post, S., Cardiovascular Research Day., "M-CSF Regulates Expression of the Adaptor Protein Dab2," Linda & Jack Gill Heart Institute, University of Kentucky, Lexington, KY, United States. (2003).
- 4) **Du, L.**, Post, S., South East Lipid Research Conference, "Differential Regulation of LDL and Transferrin Receptor Endocytosis: Potential involvement of receptor-specific adaptor proteins," American Heart Association, Pine Mountain, GA, United States. (March 2002).
- 3) **Du, L.**, Post, S., Cardiovascular Research Day., "Differential Regulation of Transferrin and LDL Receptors by Macrophage-Colony Stimulating Factor," Linda & Jack Gill Heart Institute, University of Kentucky, Lexington, KY, United States. (2001).
- 2) **Du, L.**, Post, S., 2nd Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, "Macrophage-Colony Stimulating Factor Differentially Regulates Transferrin and LDL Receptors in Macrophages," American Heart Association, Arlington, VA, United States. (2001).
- 1) **Du, L.**, Post, S., Cardiovascular Research Day., "Macrophage-Colony Stimulating Factor Regulates Transferrin Association with Macrophages via a PI3-Kinase Signaling Pathway," Linda & Jack Gill Heart Institute, University of Kentucky, Lexington, KY, United States. (2000).

#### **V. Invited Talks, Lectures, and Presentations: (total, 17; Texas State, 4)**

- 17) **Du, L.**, Beijing University of Chinese Medicine Pain Management Forum 2019, "From raising a scientific question to a successful grant application," Dong Fang Hospital, Beijing University of Chinese Medicine, Beijing, China. (July 7, 2019).
- 16) **Du, L.**, 3rd World Congress on Cancer Biology and Immunology 2019, "Mechanisms of cell differentiation in neuroblastoma and discovery of differentiation agents for neuroblastoma



therapy," Cenetri Publishing group, Klima Hotel Milano Fiere, Milan, Italy, Milan, Italy. (March 11, 2019).

15) **Du, L.**, International Conference and Exhibition on Pediatric Oncology and Clinical Pediatrics, "Cell differentiation and differentiation therapy in neuroblastoma," Conference Series LLC, Pediatric Oncology, Pediatric Leukemia, Pediatric Hematology Oncology & Neuroblastoma in Children, Toronto, Canada. (August 11, 2016).

14) **Du, L.**, Department of Chemistry and Biochemistry. Texas State University, "Cell differentiation and differentiation therapy in neuroblastoma," San Marcos, TX. (November 23, 2015).

13) **Du, L.**, Innovative Drug Discovery & Nanotechnology session, "Identifying novel differentiation agents for neuroblastoma therapy," 2015 Drug Discovery and Therapy World Congress, Boston, United States. (July 23, 2015).

12) **Du, L.**, Session 603: Lead Discovery and Optimization, "Using high-content screening to identify novel differentiation agents for neuroblastoma," 2015 BIT's 8th Annual World Cancer Congress, Beijing, China. (May 16, 2015).

11) **Du, L.**, Department of Chemistry and Biochemistry. Texas State University, "Targeting the differentiation pathway in neuroblastoma differentiation therapy," San Marcos, TX. (December 4, 2014).

10) **Du, L.**, 2014 EDT Program Retreat, "Differentiation therapy in neuroblastoma," Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX. (November 7, 2014).

9) **Du, L.**, 2014 Cancer Therapy and Research Center Symposium, "Targeting the differentiation pathway in neuroblastoma differentiation therapy," University of Texas Health Science Center at San Antonio, San Antonio, TX. (September 26, 2014).

8) **Du, L.**, Pediatric Translational Working Group, "Targeting the differentiation pathway in neuroblastoma differentiation therapy," Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX. (July 29, 2014).

7) **Du, L.**, Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, "Cell differentiation in neuroblastoma," Baton Rouge, LA. (April 16, 2014).

6) **Du, L.**, "Drug/target discovery for neuroblastoma differentiation therapy," Department of Pediatrics Research Day. University of Texas Health Science Center at San Antonio, San Antonio, TX. (May 10, 2013).

5) **Du, L.**, Greehey Children's Cancer research Institute Annual Retreat, "Cell differentiation in neuroblastoma," University of Texas Health Science Center at San Antonio, San Antonio, TX. (February 28, 2013).

4) **Du, L.**, Department of Cellular and Structural Biology Seminar series, "The roles of microRNAs and transcription factors in lung cancer," University of Texas Health Science Center at San Antonio, San Antonio, TX. (October 16, 2012).

3) **Du, L.**, Department of Cellular and Structural Biology Annual Retreat, "From lung to pediatric cancers: how do I bridge the two?," University of Texas Health Science Center at San Antonio, San Antonio, TX. (May 17, 2012).

2) **Du, L.**, "Inter-regulation between miRNAs and STAT3 in lung cancer," Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX. (April 8, 2011).

1) **Du, L.**, Minisymposium. The 102nd Annual Meeting of the American Association for Cancer Research, "miR-337-3p and its targets STAT3 and RAP1A modulate paclitaxel sensitivity in non-small cell lung cancer (NSCLC)," Orlando, FL. (April 4, 2011).

## VI. Grants

### **A. Funded External Grants: (total, 8; \*, Texas State, 4)**

\*8) **Du, L (PI)**. Molecular and therapeutic mechanisms of differentiation-inducing microRNA miR-506-3p in neuroblastoma, National Institute of Health, NCI, Federal, \$445,639.00. (Funded: September 1, 2020 - August 31, 2023). Grant.

\*7) **Du, L (PI)**, Kornienko, Alexander (co-I), Houghton, Peter (collaborator). Discovery of new differentiation agents for neuroblastoma therapy, National Institute of Health, NCI, Federal, \$461,574.00. (Funded: August 1, 2017 - July 31, 2020). Grant.

\*6) Kerwin, S (PI), **Du, L (Co-PI)**. Hypoxia-derived treatment for advanced lung cancer, William and Ella Owens Medical Research Foundation, Private / Foundation / Corporate, \$153,109.00. (Funded: January 1, 2016 - December 31, 2017). Grant.

\*5) **Du, L (PI)**. Identifying microRNAs that induce neuroblastoma cell differentiation, Department of Defense, Federal, \$186,828.00. (Funded: September 1, 2013 - February 28, 2017). Grant. \*Transferred to Texas State.

4) **Du, L (PI)**. Identifying a novel oncogenic mechanism and diagnostic marker for neuroendocrine lung cancer, Peter Bradley Carlson Trust, \$30,000.00. (Funded: January 1, 2015 - December 31, 2015). Grant.

3) Cichewicz, Robert (PI), Mooberry, Susan (co-PI), **Du, L (co-I)**, Identify bioactive natural products from the Great Lakes fungi for treating pediatric cancers, National Institute of Health, NCI, Federal, \$861,335.00. (Funded: July 1, 2014 - June 30, 2015). Grant.

2) Pertsemlidis, A. (PI), **Du, L (Co-PI)**. What drives the regression in neuroblastoma? Clues from Chromosome 21, Helen Freeborn Kerr Foundation Award, Private / Foundation / Corporate, \$4,000.00. (Funded: July 1, 2014 - June 30, 2015). Grant.

1) **Du, L (PI)**. Discovery of new drugs for neuroblastoma from Texas plants, Bank of America Shelby Rae Tengg Foundation, Private / Foundation / Corporate, \$5,000.00. (Funded: July 1, 2013 - June 30, 2014). Grant.

### **B. Funded Internal Grants: (total, 6; \*, Texas State, 2)**

\*6) **Du, L (PI)**. Developing novel miR-506-3p analogs that induce neuroblastoma cell differentiation, REP Program, Texas State University, Texas State University, \$8,000.00. (Funded: January 15, 2020 - December 31, 2021). Grant.

\*5) **Du, L (PI)**. Determining the therapeutic potential of rooperol in neuroblastoma, REP Program, Texas State University, Texas State University, \$8,000.00. (Funded: January 1, 2017 - May 31, 2018). Grant.

4) Pertsemlidis, A (PI), **Du, L (Co-PI)**. Elucidating how chromosome 21 protects against neuroblastoma occurrence, Institute for Integration of Medicine and Science, Institutional (Higher Ed), \$50,000.00. (Funded: October 4, 2014 - September 30, 2015). Grant.

3) **Du, L (PI)**. Identifying microRNAs that regulate LMO1 expression in neuroblastoma, Greehey Children's Cancer Research Institute, Institutional (Higher Ed), \$8,100.00. (Funded: August 1, 2013 - July 31, 2015). Grant.

2) **Du, L (PI)**. Identifying long non-coding RNAs controlling neuroblastoma cell differentiation, Institute for Integration of Medicine and Science, Institutional (Higher Ed), \$50,000.00. (Funded: December 1, 2013 - November 30, 2014). Grant.

1) **Du, L (PI)**. Pilot investigation of the role of microRNAs in regulating neuroblastoma cell differentiation, Greehey Children's Cancer Research Institute, Other, \$10,000.00. (Funded: September 1, 2012 - August 31, 2013). Grant.